2018年中国肺血栓栓塞症诊治与预防指南质量评价
该研究采用AGREE Ⅱ工具评价中国2018年肺血栓栓塞症诊治与预防指南的方法学质量,六个领域得分范围为55.2%至83.3%,指南被推荐临床使用;101条推荐中高、中、低级证据分别占7条(6.9%)、31条(30.7%)和63条(62.4%),提示方法学质量整体较高但证据级别不高。
要点
- 该指南AGREE Ⅱ各领域得分:范围和目的76.4%、参与人员55.6%、制定的严谨性78.1%、表达的明晰性83.3%、应用性55.2%、编辑独立性66.7%。
- 101条推荐中高、中、低级证据分别占7条(6.9%)、31条(30.7%)和63条(62.4%)。
- 参与人员和应用性领域得分较低,未来更新应加强并纳入经济学证据及患者偏好。
核心结论
- 该指南方法学质量整体较高但证据级别不高,参与人员和应用性领域需加强。
研究设计与样本
- 采用AGREE Ⅱ工具评价中国2018年肺血栓栓塞症诊治与预防指南,包含6个领域23个条目和2个总体评估条目,每条目1至7分。
主要发现
- AGREE Ⅱ六领域得分:范围和目的76.4%、参与人员55.6%、制定的严谨性78.1%、表达的明晰性83.3%、应用性55.2%、编辑独立性66.7%。
- 该指南被推荐用于临床。
- 101条推荐中高、中、低级证据分别占7条(6.9%)、31条(30.7%)和63条(62.4%)。
关键数值与推荐
- AGREE Ⅱ各领域得分:范围和目的76.4%、参与人员55.6%、制定的严谨性78.1%、表达的明晰性83.3%、应用性55.2%、编辑独立性66.7%。
- 101条推荐中高证据7条(6.9%)、中证据31条(30.7%)、低证据63条(62.4%)。
临床怎么用
- 该指南可推荐临床使用,但应用中需注意多数推荐基于低级别证据。
- 未来制定指南应加强参与人员和应用性,纳入经济学研究证据及患者与公众偏好。
局限性
- 原文未报告评价者数量、一致性检验等具体方法学细节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To assess the quality of the clinical practice guideline for diagnosis, treatment and prevention of pulmonary thromboembolism, 2018 in China, providing the references for updating and developing clinical practice guidelines of this field in the future. Methods: The quality of the clinical practice guideline for diagnosis, treatment and prevention of pulmonary thromboembolism, 2018 in China was assessed using the internationally recognized instrument Appraisal of Guidelines for Research and Evaluation Ⅱ (AGREE Ⅱ). AGREE Ⅱ instrument consisted of 23 items in six domains, followed by two overall assessment items. Each item was scored from 1 to 7. The final overall guideline quality considered all domain items. Results: The scores of the six AGREE Ⅱ domains were: Scope and purpose 76.4%, Stakeholder involvement 55.6%, Rigor of development 78.1%, Clarity and presentation 83.3%, Applicability 55.2%, and Editorial independence 66.7%. The guideline was recommended for clinical use. Among the 101 recommendations, recommendations based on Levels High, Moderate and Low evidence accounted for 7 (6.9%), 31 (30.7%) and 63 (62.4%), respectively. Conclusion: The methodological quality of the clinical practice guideline for diagnosis, treatment and prevention of pulmonary thromboembolism, 2018 in China was great, but the levels of evidence were not high. More efforts were urgently required to improve in Stakeholder involvement and applicability. Especially corresponding economic research evidence, as well as preferences of patients and the public should be considered in the future development of clinical practice guidelines. 目的: 评价国内2018年发布的"肺血栓栓塞症诊治与预防指南"的质量,为今后更新和制定我国临床实践指南提供借鉴和参考。 方法: 利用国际公认的指南质量评价工具AGREE Ⅱ(appraisal of guidelines for research and evaluation Ⅱ)对我国2018年发布的"肺血栓栓塞症诊治与预防指南"进行质量评价。AGREE Ⅱ总共包含6个领域共23个条目和2个总体评估条目,每个条目得分为1~7分,综合考虑所有领域和条目来评估指南的质量。 结果: 该指南AGREE Ⅱ六个领域中"范围和目的"得分76.4%、"参与人员"得分55.6%、"制定的严谨性"得分78.1%、"表达的明晰性"得分83.3%、"应用性"得分55.2%、"编辑独立性"得分66.7%。该指南在临床推荐使用。在101条推荐中,高、中、低级证据分别占7条(6.9%)、31条(30.7%)和63条(62.4%)。 结论: 国内2018年发布的"肺血栓栓塞症诊治与预防指南"的方法学质量整体较高但证据级别不高,得分较低的"参与人员"和"应用性"两个领域仍需加强,特别是应纳入相应的经济学研究证据并进一步重视患者及公众的利益和偏好。.
引用
- Wan KR, Lai N, Ma JL, et al. [Quality assessment of the clinical practice guideline for diagnosis, treatment and prevention of pulmonary thromboembolism, 2018]. Zhonghua Jie He He Hu Xi Za Zhi. 2019. PMID: 30845399. doi:10.3760/cma.j.issn.1001-0939.2019.03.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。